Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hexacima 3-dose primary series safety study in infants in Poland and the Russian Federation
2013-003267-55Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jul 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pertussis filamentous haemagglutinin in diphtheria, Tetanus, pertussis and 3 more, sponsored by Sanofi. Primary endpoint: Occurrence of unsolicited systemic adverse events. Started Jul 2015; status: completed.
02
Drugs
pertussis filamentous haemagglutinin
03
Conditions
diphtheriaTetanuspertussispoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on 2013-003267-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003267-55.